Coenzyme Q10 in Juvenile Idiopathic Arthritis Patients
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatological disorder in
childhood of unknown cause and a major cause of functional disability. Standard JIA treatment
including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, methotrexate, and
biological agents have considerable adverse effects in addition to their high cost. Despite
the success of these treatment approaches, patients may still have active disease with other
sequelae from chronic inflammation and considerable morbidity that may negatively impact
patients' quality of life. Therefore, evaluating the potential benefit of alternative add-on
anti-inflammatories and antioxidants might be a promising area for further research. Coenzyme
Q10 (CoQ10) is a natural mitochondrial electron carrier and a powerful lipophilic antioxidant
located in almost all cell membranes and plasma lipoproteins. Several preclinical studies in
animal models as well as clinical trials in adult patients with rheumatoid arthritis (RA)
have demonstrated the beneficial effects of CoQ10. Results show that CoQ10 can reduce the
oxidative and inflammatory status as well as clinical features that characterize this
systemic autoimmune disease.
Also, CoQ10 has been used safely in children before and was well tolerated. Thus, we would
like to investigate the effect of CoQ10 oral supplementation in pediatric JIA patients.